Clik here to view.
Sinovac Amends Shareholder Rights Plan
BEIJING Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its...
View ArticleClik here to view.
三叶草与葛兰素史克合作评估新型冠状病毒候选疫苗与大流行疫苗佐剂系统的联用
中国成都、英国伦敦 (美国商业资讯)–今天，三叶草生物制药有限公司（以下简称“三叶草生物”）宣布将与葛兰素史克（GSK）开展研发合作，推动其基于蛋白的新型冠状病毒候选疫苗“COVID-19...
View ArticleClik here to view.
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus...
CHENGDU, China & LONDON Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today...
View ArticleClik here to view.
Clik here to view.
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive...
NEW YORK Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of...
View ArticleClik here to view.
Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of...
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced FETROJA® (cefiderocol) is now available in the U.S. for patients 18 years of age or older who...
View ArticleClik here to view.
Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the...
View ArticleClik here to view.
Clik here to view.
ClinOne Offers Complimentary Support to Researchers Racing to Develop the...
DENVER In December 2019, cases of Influenza, primarily Influenza A and Influenza B, were climbing dramatically within the United States. Globally, Influenza A was in full force, with symptoms...
View ArticleClik here to view.
Promega Custom Manufacturing Capabilities Aid in Rapid Development of...
MADISON, Wis. Promega Corporation is being recognized by Utah-based Co-Diagnostics, Inc. for the support Promega custom manufacturing provided in the rapid development and launch of the new Logix...
View ArticleClik here to view.
Clik here to view.
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO®...
LONDON Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1....
View ArticleClik here to view.
Arima GenomicsがシリーズAの資金調達を完了
サンディエゴ （ビジネスワイヤ） — ゲノムのシーケンスと構造がヒトの健康と疾患で果たす役割についての理解を促進するための研究ツールに主眼を置く企業のArima Genomics, Inc.は、シリーズAラウンドの資金調達が完了したことを発表します。アジレント・テクノロジー（NYSE: A）とCowin Venture（凱風創投）が本ラウンドを主導し、Vectr...
View ArticleClik here to view.
Arima Genomics完成A轮融资
圣迭戈 (美国商业资讯)–Arima Genomics, Inc.是一家专注于研究工具的公司，这些工具用于增进对基因组顺序和结构的认识，从而了解其在人类健康和疾病中的作用，该公司宣布已完成A轮融资。Agilent Technologies, Inc. (NYSE: A)和Cowin Venture领投，Vectr Ventures和Berkeley Catalyst Fund跟投。...
View ArticleClik here to view.
武田宣布美国FDA授予ALUNBRIG® (brigatinib)作为ALK+转移性非小细胞肺癌一线治疗的补充新药申请优先审理
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，美国食品药品管理局(FDA)已授予该公司ALUNBRIG...
View ArticleClik here to view.
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of...
View ArticleClik here to view.
武田薬品、ALK陽性転移性非小細胞肺がんに対するファーストライン治療薬としてのALUNBRIG®（ブリガチニブ）の適応追加申請を米国FDAが優先審査に指定と発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and Taiho Pharmaceutical Co. Ltd., (“Taiho”),...
View ArticleClik here to view.
Bioventus认可EXOGEN长达25年经过验证的骨愈合功效
北卡罗莱纳州达勒姆 (美国商业资讯)–骨科解决方案的全球领导者Bioventus认可其EXOGEN超声骨愈合系统长达25年经过验证的骨愈合功效。EXOGEN使用低强度脉冲超声波(LIPUS)来帮助刺激机体的自然骨愈合机制并促进骨折愈合。对于无法自行愈合的骨折，其愈合率达86% 1，对于有适应证的新发骨折，愈合速度提高38% 2, 3。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
New Cancer Treatment Developed at NTHU
HSINCHU, Taiwan A research team led by Dr. Yunching Chen and Tsai-Te Lu of National Tsing Hua University have recently developed a new treatment for cancer, in which blood vessels within malignant...
View Article